Indonesia’s National Agency of Drug and Food Control (BPOM) is easing import regulations for pharmaceutical raw materials. This move aims to mitigate potential price increases of medications caused by the rupiah’s recent depreciation against the US dollar. The regulatory adjustments are intended to help domestic pharmaceutical companies manage production costs. BPOM anticipates these changes will stabilize drug prices for consumers. The agency has not specified the exact nature of the streamlined processes, but indicated a focus on reducing bureaucratic hurdles. This action reflects concerns about affordability and access to essential medicines amid economic pressures. The initiative seeks to ensure a consistent supply of pharmaceuticals despite currency fluctuations.